The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Lilly
Research Funding - Eisai (Inst); Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
Multi-institutional european single-arm phase II trial of pazopanib in advanced typical solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.
 
Josefina Cruz Jurado
Honoraria - Amgen; Eisai; Lilly; Novartis; Pfizer; PharmaMar; Roche
 
Sarah Naomie Dumont
No Relationships to Disclose
 
Nicolas Penel
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag
Other Relationship - PharmaMar
 
Pablo Luna Fra
No Relationships to Disclose
 
Enrique Alava
No Relationships to Disclose
 
Nadia Hindi
No Relationships to Disclose
 
Jean-Yves Blay
Honoraria - Bayer; GlaxoSmithKline; Novartis
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
 
Silvia Stacchiotti
Honoraria - Lilly; PharmaMar; Takeda
Consulting or Advisory Role - Bayer; Epizyme; Immune Design; Lilly; MaxiVax; PharmaMar
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Paola Collini
No Relationships to Disclose
 
Andres Redondo
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; PharmaMar; Roche; Tesaro
Research Funding - Eisai (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche
 
Daniel Bernabeu
No Relationships to Disclose
 
Antonio Lopez-Pousa
No Relationships to Disclose
 
Giovanni Grignani
Honoraria - Bayer; Eisai; Lilly; Novartis; PharmaMar
Consulting or Advisory Role - Bayer; Eisai; Lilly; Novartis; PharmaMar
Research Funding - Bayer (Inst); Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
David Silva Moura
Research Funding - Eisai (Inst); Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Javier Martinez-Trufero
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Lilly; Merck; PharmaMar
Travel, Accommodations, Expenses - Merck; PharmaMar; PharmaMar
 
Philippe Terrier
No Relationships to Disclose
 
Marie Karanian
No Relationships to Disclose
 
Axel Le Cesne
Honoraria - Amgen; Bayer; Lilly; Novartis; Pfizer; PharmaMar
 
Paolo Giovanni Casali
Honoraria - Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - ARIAD/Merck; Bayer; Blueprint Medicines; Eisai; GlaxoSmithKline; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; PharmaMar
Research Funding - Amgen/Dompé (Inst); Bayer (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MolMed (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Javier Martin Broto
Honoraria - Lilly; PharmaMar
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Novartis; PharmaMar
Speakers' Bureau - PharmaMar
Research Funding - Eisai (Inst); GlaxoSmithKline; Lilly (Inst); Novartis (Inst); PharmaMar
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar